WallStreetZenWallStreetZen

NASDAQ: ACRS
Aclaris Therapeutics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

ACRS past revenue growth

How has ACRS's revenue growth performed historically?
Company
5.03%
Industry
0.12%
Market
17.2%
ACRS's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
ACRS's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
ACRS's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

ACRS earnings and revenue history

Current Revenue
$31.2M
Current Earnings
-$88.5M
Current Profit Margin
-283.1%

ACRS Return on Equity

Current Company
-52.8%
Current Industry
-24%
Current Market
188%
ACRS's Return on Equity (-52.8%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when ACRS announces earnings.

ACRS Return on Assets

Current Company
-40.2%
Current Industry
6.7%
ACRS is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

ACRS Return on Capital Employed

Current Company
-53.38%
Current Industry
11.6%
ACRS has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

ACRS vs Diagnostic & Research Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
ACRS$31.25M-$87.99M-$88.48M+38.41%N/A
BNR$74.64MN/A-$90.79M+20.19%N/A
PRPH$44.38M-$14.83M-$16.78M+27.59%N/A
VNRX$775.30k-$33.68M-$35.32M+159.50%N/A
STIM$71.35M-$22.76M-$30.19M+6.22%N/A
View Top Diagnostic & Research Stocks

ACRS earnings dates

Next earnings date
May 6, 2024

Aclaris Therapeutics Earnings & Revenue FAQ

What were ACRS's earnings last quarter?

On Invalid Date, Aclaris Therapeutics (NASDAQ: ACRS) reported Q4 2023 earnings per share (EPS) of -$0.02, up 95.12% year over year. Total Aclaris Therapeutics earnings for the quarter were -$1.49 million. In the same quarter last year, Aclaris Therapeutics's earnings per share (EPS) was -$0.41.

If you're new to stock investing, here's how to buy Aclaris Therapeutics stock.

What was ACRS's earnings growth in the past year?

As of Q2 2024, Aclaris Therapeutics's earnings has grown year over year. Aclaris Therapeutics's earnings in the past year totalled -$88.48 million.

What is ACRS's earnings date?

Aclaris Therapeutics's earnings date is Invalid Date. Add ACRS to your watchlist to be reminded of ACRS's next earnings announcement.

What was ACRS's revenue last quarter?

On Invalid Date, Aclaris Therapeutics (NASDAQ: ACRS) reported Q4 2023 revenue of $17.57 million up 126.62% year over year. In the same quarter last year, Aclaris Therapeutics's revenue was $7.75 million.

What was ACRS's revenue growth in the past year?

As of Q2 2024, Aclaris Therapeutics's revenue has grown 5.03% year over year. This is 4.91 percentage points higher than the US Diagnostics & Research industry revenue growth rate of 0.12%. Aclaris Therapeutics's revenue in the past year totalled $31.25 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.